Cambridge, UK / October 17th 2023 / Domainex, a leading integrated medicines research services partner, is thrilled to announce its recent success in multiple prestigious business awards. The company received a King’s Award for Enterprise earlier this year and its commitment to excellence and innovation has been further recognised by the following accolades:
- Life Science Scale-Up at the Business Weekly Awards
- Gold for High Growth Business of the Year and Silver for Business of the Year (>50 employees) at the Cambridge Independent SME Awards
The company will now progress to the National SME Awards in the High Growth Business of the Year category and winners will be announced at an awards ceremony on 1st December 2023.
Over the past year, Domainex has demonstrated remarkable growth and achievements. The company reported an impressive 19% increase in revenues in 2022, building upon an exceptional 24% growth in the previous year. This growth has been entirely organic, underscoring Domainex's reputation and commitment to excellence. Furthermore, Domainex expanded its team by over 30 members, representing a 40% increase in staff.
The company formed significant partnerships, including a ground-breaking collaboration with NRG Therapeutics focused on developing novel small molecule disease-modifying medicines for Parkinson's disease, MND, and other neurodegenerative disorders. Domainex has also recently launched a number of new services including Cryogenic Electron Microscopy (Cryo-EM), Flow Cytometry and Isothermal Titration Calorimetry (ITC).
Looking ahead, Domainex remains dedicated to its vision of continued organic growth and has ambitious plans to double its revenue over the next three years. Domainex will continue to invest in state-of-the-art equipment and services, expand its research facilities, and launch new service offerings to expand its capabilities.
Tom Mander, CEO of Domainex, commented: “These awards recognise the stellar work from the Domainex team over the past year. The diligence they show when solving complex challenges for our clients and partners has enabled us to deliver effective and innovative solutions, growing our portfolio of customers and driving business success.”
These awards are a testament to Domainex's dedication to providing cutting-edge research services. The company has also been shortlisted as a finalist for several other upcoming awards including:
- Business Development Team of the Year at the SCRIP awards
- Most Impactful CRO and Most Impactful Industry Collaboration at the OBN awards while Domainex’s Head of Chemistry, Dr Andrew Ratcliffe, has been shortlisted for the Special Recognition Award
- Employer of the Year, The Bridges Positive Impact Award and Growing Business of the Year: Turnover £10m-£15m at the Growing Business awards
The upcoming awards will be announced over the next couple of months, follow Domainex on X (formerly Twitter) or LinkedIn for further updates.